Andrew Dreyfus

CIK: 0001670893

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ANRO

Alto Neuroscience, Inc.

Director

IRWD

IRONWOOD PHARMACEUTICALS INC

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

ANRO
Alto Neuroscience, Inc.
May 12, 2026
Award(A)
Stock Option (right to buy)
Direct
11K shares-
IRWD
IRONWOOD PHARMACEUTICALS INC
Jun 10, 2025
Award(A)
Direct
45K shares-
ANRO
Alto Neuroscience, Inc.
May 13, 2025
Award(A)
Stock Option (right to buy)
Direct
15.3K shares-

		Type	Shares	Price		Ownership
May 12, 2026	ANRO Alto Neuroscience, Inc.	Award(A) Stock Option (right to buy)	10,958	-	-	Direct
Jun 10, 2025	IRWD IRONWOOD PHARMACEUTICALS INC	Award(A)	45,000	-	-	Direct
May 13, 2025	ANRO Alto Neuroscience, Inc.	Award(A) Stock Option (right to buy)	15,287	-	-	Direct

1-3 of 3 transactions

About Dreyfus Andrew

Dreyfus Andrew (SEC CIK 0001670893) files insider reports with the SEC as Director of Alto Neuroscience, Inc. (ANRO) and Director of IRONWOOD PHARMACEUTICALS INC (IRWD).

Signal8 holds 3 ownership filings by Dreyfus Andrew, all Form 4s, filed between May 15, 2025 and May 14, 2026. Those filings report 3 transactions, from May 13, 2025 to May 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dreyfus Andrew's filings is in MOUNTAIN VIEW, CA.

Recent filings by Dreyfus Andrew

May 12, 2026: Grant or award of ANRO derivative securities (Form 4, code A).
Jun 10, 2025: Grant or award of IRWD shares (Form 4, code A).
May 13, 2025: Grant or award of ANRO derivative securities (Form 4, code A).

Other insiders filing for Alto Neuroscience, Inc. (ANRO)

Smith Nicholas Conrad, PRESIDENT AND CFO
Miller Andrew Craig, Director
Etkin Amit, PRESIDENT AND CEO
Sanchez Ramiro, Director
Cox Christopher Nixon, Director
Manji Husseini, Director

How to read Form 4 transaction codes